TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05383235

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ROUTINE CARE
Description: 1. ROUTINE CARE : retrieval of sociodemographic characteristics, medical and psychological assessment, multidisciplinary meeting about the patient

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Facial emotion stimuli prensentation task with EEG recording and facial emotion recognition task
Description: 2. RUN-IN PERIOD :~* Eligibility criteria will be assessed during the multidisciplinary meeting;~* Study presentation, delivery of the information note and consent form; 3. STUDY:~* Collection of consent form;~* Facial emotion stimuli presentation task with EEG recording and facial emotion recording task;~* Neuropsychological evaluation (TOM-15);~* Scales and questionnaires (TAS-20, PCL-R SV, CECAQ, QCAE);~* Debriefing.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Facial emotion stimuli prensentation task with EEG recording and facial emotion recognition task
Description: 2. RUN-IN PERIOD :~* Eligibility criteria will be assessed during the multidisciplinary meeting;~* Study presentation, delivery of the information note and consent form; 3. STUDY:~* Collection of consent form;~* Facial emotion stimuli presentation task with EEG recording and facial emotion recording task;~* Neuropsychological evaluation (TOM-15);~* Scales and questionnaires (TAS-20, PCL-R SV, CECAQ, QCAE);~* Debriefing.
Study: NCT05825248

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fine and gross motor treatment only
Description: occupational therapy intervention involving general fine and gross motor activities

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reflex integration + fine and gross motor treatment
Description: occupational therapy intervention involving general fine and gross motor activities as well as targeted reflex integration exercises
Study: NCT04537611

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: dHb contrast and gadolinium contrast imaging
Description: see arm description
Study: NCT06054529

Intervention type: PROCEDURE
Intervention: Surgical removal of the GBM tumor
Description: Surgical removal of the GBM tumor

Intervention type: OTHER
Intervention: d4-NAM infusion
Description: Following the surgical removal of the GBM tumor, GBM patients will be dosed with a form of nicotinamide (a natural vitamin) that we can track. The nicotinamide will be converted to methyl nicotinamide (MeNAM) in the tumor. We will measure how fast the nicotinamide is converted to methyl nicotinamide. We believe that the speed of this chemical reaction in the tumor (fast versus slow) may be correlated with GBM aggressiveness.
Study: NCT04836949

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shear Wave Elastography of prostate
Description: A 12-core template biopsy is planned as during a conventional prostate biopsy. The prostate is divided in to 1) Rt apex, 2) Rt mid, 3) Rt base, 4) Rt apex lateral, 5) Rt mid lateral, 6) Rt base lateral, 7) Lt apex, 8) Lt mid, 9) Lt base, 10) Lt apex lateral, 11) Lt mid lateral, and 12) Lt base lateral areas. The elasticity of each area is evaluated and region with the maximum Young's modulus value is selected and targeted for biopsy. Additional biopsy for suspicious lesions can be performed at the discretion of the practitioner.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Prostate Ultrasound
Description: A conventional 12-core template biopsy is planned. The prostate is divided in to 1) Rt apex, 2) Rt mid, 3) Rt base, 4) Rt apex lateral, 5) Rt mid lateral, 6) Rt base lateral, 7) Lt apex, 8) Lt mid, 9) Lt base, 10) Lt apex lateral, 11) Lt mid lateral, and 12) Lt base lateral areas. Random biopsy of each area is performed. Additional biopsy of suspicious hypoechoic nodular lesions can be performed at the discretion of the practitioner.
Study: NCT06006975

Intervention type: RADIATION
Intervention: Computed Tomography (CT) and Computed Tomography Angiography (CTA)
Description: CT and CTA examinations are performed as a routine procedure to evaluate SAH severity and to diagnose cerebral vasospams and delayed cerebral ischemia.

Intervention type: DIAGNOSTIC_TEST
Intervention: Multimodal physiological monitoring
Description: Patients are monitored routinely during their treatment in ICU. Multimodal physiological monitoring include continuous monitoring of arterial blood pressure (ABP), intracranial pressure (ICP) (if available), ETCO2 (if available), cerebral perfusion pressure (if available), cerebral blood flow velocity (CBFV) measured in middle cerebral artery and heart rate.~Non invasive CBFV will be measured by using TCD device DWL Multi Dop-T. Invasive ICP will be measured by using Codman ICP Express or Raumedic ICP monitor.
Study: NCT05827159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone Pill
Description: In the MAUD component, some participants will receive oral Naltrexone in the ED.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone Injection
Description: In the MAUD component, some participants will receive a dose of XR-NTX (injection) in the ED.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Negotiation Interview
Description: Brief Negotiation Interview (BNI) has four key components: (1) permission to discuss substance use, (2) feedback on the health consequences of ongoing substance use, including making a connection between the ED visit and substance use, (3) motivational enhancement, and (4) negotiation and advice.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Negotiation Interview
Description: Brief Negotiation Interview (BNI) has four key components: (1) permission to discuss substance use, (2) feedback on the health consequences of ongoing substance use, including making a connection between the ED visit and substance use, (3) motivational enhancement, and (4) negotiation and advice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin Pill
Description: In the MAUD component, ancillary treatment with gabapentin will be provided.
Study: NCT04749394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab, PD-1 monoclonal antibody
Description: Camrelizumab 200mg IV, Q3W, until clinical progression/deterioration or confirmed radiological progression, or up to 1 year.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib, VEGFR2 antibody
Description: Apatinib 250mg PO, QD, until clinical progression/deterioration or confirmed radiological progression, or up to 1 year.
Study: NCT05745870

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine Monohydrate Supplementation
Description: Participants will consume 5g/d creatine monohydrate + 5g/d maltodextrin for 42 consecutive days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Creatine Monohydrate Supplementation
Description: Participants will consume 5g/d creatine monohydrate + 5g/d maltodextrin for 42 consecutive days
Study: NCT05651945

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation program
Description: The cardiac rehabilitation program is an outpatient exercise intervention consisting of 36 sessions (30-50 minutes) of a progressive exercise program. Participants are closely monitored throughout the sessions using a telemetry monitor and are supervised by a team of cardiac rehabilitation nurses and exercise physiologists. In addition to the exercise program, participants will receive educational sessions for cardiovascular disease (CVD) risk factors including: 1) Diet/Nutrition, 2) Smoking cessation, 3) Physical activity, 4) Medication management/adherence and 5) Behavior change. As a part of the program, based on the initial assessment results, patients are referred to a rehabilitation psychologist or a dietician for consultation and evaluation if needed. In addition, participants will also receive their standard of care therapies as prescribed by their treating physicians.
Study: NCT05277974

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: inj bupivicain
Description: In goup B 30ml of inj. bupivicaine only will be given in Erector Spinae Plane Block and In Group D inj Bupivicain plus inj dexamethasone will be given

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: inj bupivicain
Description: In goup B 30ml of inj. bupivicaine only will be given in Erector Spinae Plane Block and In Group D inj Bupivicain plus inj dexamethasone will be given
Study: NCT06281392

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CADe system
Description: Colonoscopy assisted by an artificial intelligence system (CADe).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NBI
Description: Virtual colonoscopy assisted by NBI
Study: NCT06310148

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: The Chronic Disease Co-Care (CDCC) Pilot Scheme
Description: Participants will receive comprehensive health management plans and necessary medication treatment from family doctors, based on their clinical condition. Nurse clinic will provide disease prevention education, health assessment, and counselling services, whereas allied health professionals (including optometrists, podiatrists, dietitians, and physiotherapists) will provide individualized intervention services for participants.
Study: NCT05122286

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bailout angioplasty
Description: Use balloons or stents for bailout angioplasty

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapy
Description: Stop the endovascular recanalization procedure or to perform further recanalization attempts using stent-retrievers and/or aspiration catheters
Study: NCT05136274

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medical treatment
Description: The surgical treatment group can be laparoscopically or by laparotomy, using the Linear Salpingostomy technique. Follow-up with β fraction of chorionic gonadotropin on days 0, 3, 7 and 14 together with gynecological abdominal or transvaginal ultrasound on day 0 and 7 and hysterosalpingography will be performed after three months of treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medical treatment
Description: The surgical treatment group can be laparoscopically or by laparotomy, using the Linear Salpingostomy technique. Follow-up with β fraction of chorionic gonadotropin on days 0, 3, 7 and 14 together with gynecological abdominal or transvaginal ultrasound on day 0 and 7 and hysterosalpingography will be performed after three months of treatment.
Study: NCT05395676

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Exergame home training programme
Description: Each training programme (Xbox or Wii Fit) is aimed at improving the following issues: improper weight shifting and reduced dual tasking. The participants will be guided in the first sessions to familiarize themselves with the exercises. Then, they will be allowed to exercise independently at home. Allowing enough practice time before collecting data helps minimize practice effects. practice effects are confounding factors that can affect the results and make it difficult to identify whether the improvement in outcome is due to the training or not. The duration of the training programme will be approximately 30 minutes. Each game will be played three times (the duration for each game is approximately one minute).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exergame home training programme
Description: Each training programme (Xbox or Wii Fit) is aimed at improving the following issues: improper weight shifting and reduced dual tasking. The participants will be guided in the first sessions to familiarize themselves with the exercises. Then, they will be allowed to exercise independently at home. Allowing enough practice time before collecting data helps minimize practice effects. practice effects are confounding factors that can affect the results and make it difficult to identify whether the improvement in outcome is due to the training or not. The duration of the training programme will be approximately 30 minutes. Each game will be played three times (the duration for each game is approximately one minute).
Study: NCT06131853

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: survey evaluation
Description: assessment of physical activity, fatigue, fear of movement, and quality of life

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: survey evaluation
Description: assessment of physical activity, fatigue, fear of movement, and quality of life
Study: NCT04899635

Intervention type: OTHER
Intervention: In-vitro contractile fatigue protocol
Description: Using contractility assays for muscle slices or the work-loop assay for isolated heart cells, the tissue preparation will undergo a series of contraction and relaxation under varying levels of preload, afterload, stimulation frequency and under other experimental conditions such as drug-induced inotropism.

Intervention type: OTHER
Intervention: In-vitro contractile fatigue protocol
Description: Using contractility assays for muscle slices or the work-loop assay for isolated heart cells, the tissue preparation will undergo a series of contraction and relaxation under varying levels of preload, afterload, stimulation frequency and under other experimental conditions such as drug-induced inotropism.
Study: NCT05494307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terbutaline
Description: Orally terbutaline at a dose of 2.5 mg three times daily for 16 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Danazol
Description: Orally danazol at a dose of 200 mg twice daily for 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danazol
Description: Orally danazol at a dose of 200 mg twice daily for 16 weeks
Study: NCT02018692

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alga Dunaliella Bardawil powder
Description: 9 cis beta carotene rich Alga Dunaliella Bardawil powder

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Alga Dunaliella Bardawil powder
Description: 9 cis beta carotene rich Alga Dunaliella Bardawil powder

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo:Starch
Description: Starch powder

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo:Starch
Description: Starch powder
Study: NCT06122363

Intervention type: DEVICE
Intervention: hysteroscopy
Description: uterine hysteroscopy right after Novasure endometrial ablation

Intervention type: DEVICE
Intervention: hysteroscopy
Description: uterine hysteroscopy right after Novasure endometrial ablation
Study: NCT04284293

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CNS10-NPC implantation
Description: All patients will receive a single, unilateral, subretinal injection of CNS10-NPC
Study: NCT05951660

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational intervention
Description: Different teaching sessions are used for patients and healthcare professionals, respectively.~The teaching sessions are held at the Assertive Community Treatment (ACT) Centers from which the patients are recruited. The duration is 3x30 minutes with breaks for patients and 60 minutes for healthcare professionals. Teaching sessions are held by two doctors a specialist in clinical pharmacology and a specialist in psychiatry and clinical sexology providing the participants with knowledge and tools for the dialogue on SD and drug-related side effects.~The topics of the teaching sessions are:~* What is sexuality?~* How psychopharmacology influences sexuality~* What can be done?~The topics will be addressed in a mixture of short informative talks using a PowerPoint presentation, group discussions, and exchanges of personal experiences.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational intervention
Description: Different teaching sessions are used for patients and healthcare professionals, respectively.~The teaching sessions are held at the Assertive Community Treatment (ACT) Centers from which the patients are recruited. The duration is 3x30 minutes with breaks for patients and 60 minutes for healthcare professionals. Teaching sessions are held by two doctors a specialist in clinical pharmacology and a specialist in psychiatry and clinical sexology providing the participants with knowledge and tools for the dialogue on SD and drug-related side effects.~The topics of the teaching sessions are:~* What is sexuality?~* How psychopharmacology influences sexuality~* What can be done?~The topics will be addressed in a mixture of short informative talks using a PowerPoint presentation, group discussions, and exchanges of personal experiences.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational intervention
Description: Different teaching sessions are used for patients and healthcare professionals, respectively.~The teaching sessions are held at the Assertive Community Treatment (ACT) Centers from which the patients are recruited. The duration is 3x30 minutes with breaks for patients and 60 minutes for healthcare professionals. Teaching sessions are held by two doctors a specialist in clinical pharmacology and a specialist in psychiatry and clinical sexology providing the participants with knowledge and tools for the dialogue on SD and drug-related side effects.~The topics of the teaching sessions are:~* What is sexuality?~* How psychopharmacology influences sexuality~* What can be done?~The topics will be addressed in a mixture of short informative talks using a PowerPoint presentation, group discussions, and exchanges of personal experiences.
Study: NCT05451069

Intervention type: DIAGNOSTIC_TEST
Intervention: Neurofilament Light Chain ,Chitinase-3 Like-1 Protein Levels and Tolerogenic plasmacytoid Dendritic Cells
Description: 1. Serum and CSF levels assay of NfL and CHI3L1 using the enzyme linked immunosorbent assay kits (ELISA).~2. Peripheral blood mononuclear cells (PBMC) will be obtained by Ficoll-Hypaque gradient. plasmacytoid dendritic cells will be identified in (CSF) and (PBMN) based on their selective expression of surface antigen (cluster of differentiation 303) CD303, named blood dendritic cells antigen 2 (BDCA-2).Antihuman antibodies: BDCA-2, HLA-DR , CD274 , HLA-G and CCR7 for identification of tolerogenic plasmacytoid dendritic cells using flowcytometry.

Intervention type: DIAGNOSTIC_TEST
Intervention: Neurofilament Light Chain ,Chitinase-3 Like-1 Protein Levels and Tolerogenic plasmacytoid Dendritic Cells
Description: 1. Serum and CSF levels assay of NfL and CHI3L1 using the enzyme linked immunosorbent assay kits (ELISA).~2. Peripheral blood mononuclear cells (PBMC) will be obtained by Ficoll-Hypaque gradient. plasmacytoid dendritic cells will be identified in (CSF) and (PBMN) based on their selective expression of surface antigen (cluster of differentiation 303) CD303, named blood dendritic cells antigen 2 (BDCA-2).Antihuman antibodies: BDCA-2, HLA-DR , CD274 , HLA-G and CCR7 for identification of tolerogenic plasmacytoid dendritic cells using flowcytometry.
Study: NCT05332496

Intervention type: DRUG
Intervention: PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab
Description: PD-1/PD-L1 inhibitors: atezolizumab, sintilimab, pembrolizumab, nivolumab, camrelizumab, tislelizumab, toripalimab, durvalumab, penpulimab, and other ICIs; VEGF-TKI/bevacizumab: sorafenib, lenvatinib, donafenib, apatinib, anlotinib, bevacizumab/ bevacizumab biosimilar, and other anti-angiogenesis drugs; Both PD-1/PD-L1 inhibitors and anti-angiogenesis drugs only include marketed drugs but are not limited to HCC approval.

Intervention type: PROCEDURE
Intervention: TACE
Description: TACE: cTACE (conventional TACE) or dTACE (drug-eluting beads TACE);

Intervention type: PROCEDURE
Intervention: TACE
Description: TACE: cTACE (conventional TACE) or dTACE (drug-eluting beads TACE);
Study: NCT04284293

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CNS10-NPC implantation
Description: All patients will receive a single, unilateral, subretinal injection of CNS10-NPC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CNS10-NPC implantation
Description: All patients will receive a single, unilateral, subretinal injection of CNS10-NPC
Study: NCT06518759

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional chest techniques
Description: patients will receive traditional chest techniques in the form of percussion and vibration, 2 times per day, 3 sets 5 repetitions per each set for 20 minutes, 3 times per week for 2 weeks
Study: NCT05121402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLL018
Description: a TYK2/JAK1 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLL018
Description: a TYK2/JAK1 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLL018
Description: a TYK2/JAK1 inhibitor

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: a TLL018 Placebo
Study: NCT04909606

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nurse-led prevention program
Description: Subjects randomized to the nurse-led prevention program group will be evaluated by the dedicated nurse within 2 weeks following randomization (individual assessment)~The nurse-led prevention program will include:~1. A video explaining corticosteroids related adverse events and adequate preventive measures~2. An individual interview with the trained nurse~3. A consultation with a dietetician~4. An individual sheet summarizing appropriate non-pharmacological preventive measures for the participant~5. An individual sheet summarizing appropriate pharmacological preventive measures for the referent physician~6. Phone calls at week-12, week-24 and week-36 to ensure the appropriate implementation of preventive measures

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Current care
Description: Subjects randomized to the standard of care group will receive a general summary sheet of preventive measures associated with long term corticosteroids therapy (no individual assessment) in addition to the usual care provided by their physician
Study: NCT05381506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib and Gemox
Description: Drug: Orelabrutinib Orelabrutinib 200mg, po, qd~Drug: Gemox14 Gemcitabine, Oxaliplatin
Study: NCT06292078

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Instructional Skill-Building Learning Approach (ISLA)
Description: The Inclusive Skill-building Learning Approach (ISLA) is a school-wide, multi-component, instructional and restorative alternative to exclusionary discipline that begins with universal prevention grounded in positive, preventative classroom strategies for all students, and layers on additional supports for students in need.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Instructional Skill-Building Learning Approach (ISLA)
Description: The Inclusive Skill-building Learning Approach (ISLA) is a school-wide, multi-component, instructional and restorative alternative to exclusionary discipline that begins with universal prevention grounded in positive, preventative classroom strategies for all students, and layers on additional supports for students in need.